Press release
Neuromyelitis Optica Spectrum Disorder Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Neuromyelitis Optica Spectrum Disorder Pipeline
Neuromyelitis Optica Spectrum Disorder Overview
Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). The incidence and prevalence of Neuromyelitis Optica Spectrum Disorder range from 0.05-0.40 and 0.52-4.4 per 100,000 people, respectively.
The characteristic symptoms of Neuromyelitis Optica Spectrum Disorder are either optic neuritis or myelitis, either of which may occur as the first symptom. Optic neuritis is an inflammation of the optic nerve leading to pain inside the eye which is rapidly followed by loss of clear vision (acuity).
"Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.
The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report: https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years. Neuromyelitis Optica Spectrum Disorder Key players such as - Imcyse, Aeterna Zentaris, BioThera Solutions, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment
Neuromyelitis Optica Spectrum Disorder Emerging therapies such as - Research Programme (Neuromyelitis optica), AIM Biologicals, BAT4406F, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.
In December 2019, Alexion Pharmaceuticals initiated a Phase III, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of Ravulizumab in adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with Neuromyelitis Optica Spectrum Disorder
In December 2020, Reistone Biopharma Company Limited initiated an open label Phase II clinical trial evaluating the efficacy and safety of SHR1459 in adult patients with Neuromyelitis Optical Spectrum Disorders(NMOSDs)
In May 2022, Alexion Pharmaceuticals announced that ULTOMIRIS® (ravulizumab-cwvz) met the primary endpoint in the CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment
Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type
DelveInsight's Neuromyelitis Optica Spectrum Disorder Report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:
Research Programme (Neuromyelitis optica): Imcyse
AIM Biologicals: Aeterna Zentaris
BAT4406F: BioThera Solutions
HBM9161: Harbour BioMed
SHR1459: Reistone Biopharma
Telitacicept: RemeGen
Ravulizumab: Alexion Pharmaceuticals
Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:
The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies at:
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers
Increase in Neuromyelitis Optica Spectrum Disorder prevalence
Rising awareness among the general population about Neuromyelitis Optica Spectrum Disorder Emergence of novel Neuromyelitis Optica Spectrum Disorder therapies
Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers
Dearth of skilled professionals and lack of healthcare infrastructure in developing economies
High costs for Neuromyelitis Optica Spectrum Disorder treatment
Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Assessment-
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight
Coverage: Global
Key Neuromyelitis Optica Spectrum Disorder Companies: Imcyse, Aeterna Zentaris, BioThera Solutions, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others
Key Neuromyelitis Optica Spectrum Disorder Therapies: Research Programme (Neuromyelitis optica), AIM Biologicals, BAT4406F, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others
Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers
Table of Contents
1 Neuromyelitis Optica Spectrum Disorder Report Introduction
2 Neuromyelitis Optica Spectrum Disorder Executive Summary
3 Neuromyelitis Optica Spectrum Disorder Overview
4 Neuromyelitis Optica Spectrum Disorder- Analytical Perspective In-depth Commercial Assessment
5 Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics
6 Neuromyelitis Optica Spectrum Disorder Late Stage Products (Phase II/III)
7 Neuromyelitis Optica Spectrum Disorder Mid Stage Products (Phase II)
8 Neuromyelitis Optica Spectrum Disorder Early Stage Products (Phase I)
9 Neuromyelitis Optica Spectrum Disorder Preclinical Stage Products
10 Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment
11 Neuromyelitis Optica Spectrum Disorder Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Neuromyelitis Optica Spectrum Disorder Key Companies
14 Neuromyelitis Optica Spectrum Disorder Key Products
15 Neuromyelitis Optica Spectrum Disorder Unmet Needs
16 Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers
17 Neuromyelitis Optica Spectrum Disorder Future Perspectives and Conclusion
18 Neuromyelitis Optica Spectrum Disorder Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuromyelitis Optica Spectrum Disorder Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2744711 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Neuromyelitis
Neuromyelitis Optica Market Detailed Industry Report Analysis 2025-2034
Introduction
Neuromyelitis optica (NMO), also known as Devic's disease, is a rare autoimmune disorder of the central nervous system characterized by severe inflammation of the optic nerves and spinal cord. Patients often experience vision loss, paralysis, sensory impairment, and bladder dysfunction. Once considered a variant of multiple sclerosis (MS), NMO is now recognized as a distinct condition, thanks to advancements in diagnostics such as aquaporin-4 (AQP4) antibody testing.
Though rare, NMO can…
Neuromyelitis Optica Spectrum Disorder Market
According to a new market research report published by Global Market Estimates, the Global Neuromyelitis Optica Spectrum Disorder Market is projected to grow at a CAGR of 6.2% from 2023 to 2028.
F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi (France), Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Zydus Cadila, Boehringer Ingelheim International GmbH., Apotex Inc., and AstraZeneca among others, are some of the key players in the global…
Neuromyelitis Optica Drug Market Therapeutic Survey Reviews, Analysis 2025
The report titled “Neuromyelitis Optica Drug Market” has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners, and industry experts.
The Neuromyelitis Optica Drug was valued…
Top News: Neuromyelitis Optica Spectrum Disorder Market Advancements 2019 - 2027
Neuromyelitis Optica Spectrum Disorder Market: Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of central nervous system which was previously known as Devic disease or neuromyelitis optica (NMO). It is a rare debilitating and lifelong disease characterized by inflammation in spinal cord and optic nerve.
View Report : https://www.transparencymarketresearch.com/neuromyelitis-optica-spectrum-disorder-market.html
People with neuromyelitis optica spectrum disorder experience symptoms such as paralysis, muscle weakness, and blindness. Neuromyelitis optica spectrum disorder is most common…
Neuromyelitis Optica Therapy Market 2020 Analysis and Research Report 2025
The Neuromyelitis Optica Therapy Market report is a collection of useful information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments.
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and…
Global Neuromyelitis Optica Drug Market Research Report 2016
Qyresearchreports include new market research report”Global Neuromyelitis Optica Drug Market Research Report 2016″ to its huge collection of research reports.
A new research report on the global Neuromyelitis Optica Drug market offers a 360-degree overview of it. The report discusses the market in significant details and elucidates all aspects of the global Neuromyelitis Optica Drug market likely to impact its growth trajectory in the upcoming years. Major market stimulants and deterrents…
